{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:07:07Z","timestamp":1790870827530,"version":"4.1.0"},"reference-count":34,"publisher":"The Endocrine Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Context: Hypothalamic-pituitary-adrenal (HPA) axis dysregulation may underlie disorders including obesity, depression, cognitive decline, and the metabolic syndrome. Conventional tests of HPA axis negative feedback rely on glucocorticoid receptor (GR) agonists such as dexamethasone but do not test feedback by endogenous cortisol, potentially mediated by both GR and mineralocorticoid receptors (MR).<\/jats:p>\n               <jats:p>Objective: The objective of the study was to use a combination of GR (RU38486, mifepristone) and MR (spironolactone) antagonists to explore the poorly understood activation of the HPA axis that occurs in obesity.<\/jats:p>\n               <jats:p>Design: This was a double-blind, placebo-controlled, randomized, crossover study.<\/jats:p>\n               <jats:p>Setting: The study was conducted at a clinical research facility.<\/jats:p>\n               <jats:p>Participants: Participants included 15 lean (body mass index 22.0 \u00b1 1.6 kg\/m2) and 16 overweight\/obese (body mass index 30.1 \u00b1 3.5 kg\/m2) men.<\/jats:p>\n               <jats:p>Intervention: Subjects attended on four occasions for blood and saliva sampling every 30 min between 1800 and 2200 h. At 1100 and 1600 h before visits, subjects took 200 mg spironolactone, 400 mg RU38486, 200 mg spironolactone + 400 mg RU38486, or placebo orally.<\/jats:p>\n               <jats:p>Main Outcome Measures: Serum cortisol levels after drug or placebo were measured.<\/jats:p>\n               <jats:p>Results: Cortisol levels did not differ between lean and obese after placebo. Spironolactone and RU38486 alone had modest effects, increasing cortisol by less than 50% in both groups. However, combined spironolactone plus RU38486 elevated cortisol concentrations substantially, more so in lean than obese men [2.9- (0.3) vs. 2.2 (0.3)-fold elevation, P = 0.002].<\/jats:p>\n               <jats:p>Conclusions: Combined receptor antagonist stimulation of the HPA axis reveals redundancy of MR and GR in negative feedback in humans. Obese men have impaired responses to combined receptor antagonist stimulation, suggesting impaired negative feedback by endogenous cortisol. Such an approach may be useful to dissect abnormal HPA axis control in neuropsychiatric and other disorders.<\/jats:p>","DOI":"10.1210\/jc.2008-2054","type":"journal-article","created":{"date-parts":[[2009,1,14]],"date-time":"2009-01-14T01:35:07Z","timestamp":1231896907000},"page":"1347-1352","source":"Crossref","is-referenced-by-count":47,"title":["Combined Receptor Antagonist Stimulation of the Hypothalamic-Pituitary-Adrenal Axis Test Identifies Impaired Negative Feedback Sensitivity to Cortisol in Obese Men"],"prefix":"10.1210","volume":"94","author":[{"given":"Cecilia","family":"Mattsson","sequence":"first","affiliation":[{"name":"Department of Public Health and Clinical Medicine (C.M., K.S., T.O.), Umea\u030a University Hospital, S-901 85 Umea\u030a, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca M.","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Endocrinology Unit (R.M.R., B.R.W.), University of Edinburgh, Centre for Cardiovascular Science, Queen\u2019s Medical Research Institute, Edinburgh EH16 4TJ, Scotland, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotryna","family":"Simonyte","sequence":"additional","affiliation":[{"name":"Department of Public Health and Clinical Medicine (C.M., K.S., T.O.), Umea\u030a University Hospital, S-901 85 Umea\u030a, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommy","family":"Olsson","sequence":"additional","affiliation":[{"name":"Department of Public Health and Clinical Medicine (C.M., K.S., T.O.), Umea\u030a University Hospital, S-901 85 Umea\u030a, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian R.","family":"Walker","sequence":"additional","affiliation":[{"name":"Endocrinology Unit (R.M.R., B.R.W.), University of Edinburgh, Centre for Cardiovascular Science, Queen\u2019s Medical Research Institute, Edinburgh EH16 4TJ, Scotland, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071613542307100_R1","first-page":"95","article-title":"Brain corticosteroid receptor balance and homeostatic control.","volume":"12","author":"de Kloet","year":"1991","journal-title":"Front Neuroendocrinol"},{"key":"2020071613542307100_R2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1677\/joe.0.1450201","article-title":"Glucocorticoid hypersecretion and the age-impaired hippocampus: cause or effect?","volume":"145","author":"Seckl","year":"1995","journal-title":"J Endocrinol"},{"key":"2020071613542307100_R3","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1530\/EJE-07-0455","article-title":"Glucocorticoids and cardiovascular disease.","volume":"157","author":"Walker","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"2020071613542307100_R4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1677\/joe.0.1530041","article-title":"Dexamethasone and 11-dehydrodexamethasone as tools to investigate the isozymes of 11\u03b2-hydroxysteroid dehydrogenase in vitro and in vivo.","volume":"153","author":"Best","year":"1997","journal-title":"J Endocrinol"},{"key":"2020071613542307100_R5","doi-asserted-by":"crossref","first-page":"6734","DOI":"10.1073\/pnas.0306996101","article-title":"11\u03b2-Hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics.","volume":"101","author":"Sandeep","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071613542307100_R6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1210\/jcem-59-1-25","article-title":"The new steroid analogue RU 486 inhibits glucocorticoid action in man.","volume":"59","author":"Bertagna","year":"1984","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613542307100_R7","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1073\/pnas.81.12.3879","article-title":"RU486: a steroid with antiglucocorticosteroid activity that only disinhibits the human pituitary adrenal system at a specific time of day.","volume":"81","author":"Gaillard","year":"1984","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071613542307100_R8","first-page":"466","article-title":"Effects of glucocorticoid antagonism with RU 486 on pituitary-adrenal function in patients with major depression: time-dependent enhancement of plasma ACTH secretion.","volume":"25","author":"Kling","year":"1989","journal-title":"Psychopharmacol Bull"},{"key":"2020071613542307100_R9","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1159\/000126474","article-title":"Effects of the glucocorticoid antagonist RU 486 on pituitary-adrenal function in patients with anorexia nervosa and healthy volunteers: enhancement of plasma ACTH and cortisol secretion in underweight patients.","volume":"57","author":"Kling","year":"1993","journal-title":"Neuroendocrinology"},{"key":"2020071613542307100_R10","first-page":"3176","article-title":"Mineralocorticoid receptor blockade by canrenoate increases both spontaneous and stimulated adrenal function in humans.","volume":"86","author":"Arvat","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613542307100_R11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1159\/000054384","article-title":"Mineralocorticoid receptor also modulates basal activity of hypothalamus-pituitary-adrenocortical system in humans.","volume":"68","author":"Deuschle","year":"1998","journal-title":"Neuroendocrinology"},{"key":"2020071613542307100_R12","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1159\/000126592","article-title":"Antimineralocorticoid canrenoate enhances secretory activity of the hypothalamus-pituitary-adrenocortical (HPA) axis in humans.","volume":"58","author":"Dodt","year":"1993","journal-title":"Neuroendocrinology"},{"key":"2020071613542307100_R13","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.1210\/jc.2002-020331","article-title":"The stimulatory effect of canrenoate, a mineralocorticoid antagonist, on the activity of the hypothalamus-pituitary-adrenal axis is abolished by alprazolam, a benzodiazepine, in humans","volume":"87","author":"Grottoli","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613542307100_R14","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0306-4530(00)00006-8","article-title":"Increased activity of the hypothalamus-pituitary-adrenal system after treatment with the mineralocorticoid receptor antagonist spironolactone.","volume":"25","author":"Heuser","year":"2000","journal-title":"Psychoneuroendocrinology"},{"key":"2020071613542307100_R15","first-page":"3339","article-title":"The role of mineralocorticoid receptors in hypothalamic-pituitary-adrenal axis regulation in humans.","volume":"83","author":"Young","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613542307100_R16","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1210\/endo.134.3.8119168","article-title":"Roles of type I and II corticosteroid receptors in regulation of basal activity in the hypothalamo-pituitary-adrenal axis during the diurnal trough and the peak: evidence for a nonadditive effect of combined receptor occupation.","volume":"134","author":"Bradbury","year":"1994","journal-title":"Endocrinology"},{"key":"2020071613542307100_R17","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1210\/endo.139.6.6029","article-title":"Evidence for mineralocorticoid receptor facilitation of glucocorticoid receptor-dependent regulation of hypothalamic-pituitary-adrenal axis activity.","volume":"139","author":"Spencer","year":"1998","journal-title":"Endocrinology"},{"key":"2020071613542307100_R18","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/0026-0495(92)90171-6","article-title":"Cortisol secretion in relation to body fat distribution in obese premenopausal women.","volume":"41","author":"Marin","year":"1992","journal-title":"Metabolism"},{"key":"2020071613542307100_R19","first-page":"341","article-title":"The hypothalamic-pituitary-adrenal axis in obese women with different patterns of body fat distribution.","volume":"77","author":"Pasquali","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613542307100_R20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0026-0495(82)90054-3","article-title":"Sex difference in the influence of obesity on the 24 hr mean plasma concentration of cortisol.","volume":"31","author":"Strain","year":"1982","journal-title":"Metabolism"},{"key":"2020071613542307100_R21","first-page":"1853","article-title":"Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and haemodynamic abnormalities.","volume":"83","author":"Rosmond","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613542307100_R22","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/j.1550-8528.1996.tb00546.x","article-title":"Inhibition of cortisol secretion by dexamethasone in relation to body fat distribution: a dose-response study.","volume":"4","author":"Ljung","year":"1996","journal-title":"Obes Res"},{"key":"2020071613542307100_R23","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1210\/jcem.87.1.8158","article-title":"Cortisol and ACTH response to oral dexamethasone in obesity and effects of sex, body fat distribution, and dexamethasone concentrations: a dose-response study.","volume":"87","author":"Pasquali","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613542307100_R24","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1210\/jcem.86.3.7453","article-title":"Tissue-specific dysregulation of cortisol metabolism in human obesity.","volume":"86","author":"Rask","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613542307100_R25","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1210\/jcem.86.9.7826","article-title":"Resistance to glucocorticoid feedback in obesity.","volume":"86","author":"Jessop","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613542307100_R26","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1210\/en.2002-221015","article-title":"Obese Zucker rats have reduced mineralocorticoid receptor and 11\u03b2-hydroxysteroid dehydrogenase type 1 expression in hippocampus -implications for dysregulation of the hypothalamic-pituitary-adrenal axis in obesity.","volume":"144","author":"Mattsson","year":"2003","journal-title":"Endocrinology"},{"key":"2020071613542307100_R27","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jchromb.2008.12.051","article-title":"Quantitative analysis of RU38486 (mifepristone) by HPLC triple quadrupole mass spectrometry.","volume":"877","author":"Homer","year":"2009","journal-title":"J Chromatogr B"},{"key":"2020071613542307100_R28","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1210\/jcem-61-6-1009","article-title":"RU486 inhibits peripheral effects of glucocorticoids in humans.","volume":"61","author":"Gaillard","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613542307100_R29","doi-asserted-by":"crossref","first-page":"14299","DOI":"10.1074\/jbc.M005363200","article-title":"Heterodimerization of mineralocorticoid and glucocorticoid receptors at a novel negative response element of the 5-HT1A receptor gene.","volume":"276","author":"Ou","year":"2001","journal-title":"J Biol Chem"},{"key":"2020071613542307100_R30","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/0896-6273(94)90431-6","article-title":"Heterodimerization between mineralocorticoid and glucocorticoid receptor: a new principle of glucocorticoid action in the CNS.","volume":"13","author":"Trapp","year":"1994","journal-title":"Neuron"},{"key":"2020071613542307100_R31","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1210\/jcem.83.5.4951","article-title":"Obesity and gender influence cortisol secretion and metabolism in man.","volume":"83","author":"Andrew","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613542307100_R32","first-page":"501","article-title":"Effect of fat distribution on the pharmacokinetics of cortisol in obesity.","volume":"36","author":"Lottenberg","year":"1998","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2020071613542307100_R33","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2165\/00003495-199345030-00007","article-title":"Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.","volume":"45","author":"Brogden","year":"1993","journal-title":"Drugs"},{"key":"2020071613542307100_R34","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1515\/DMDI.1987.5.4.273","article-title":"The metabolism and biopharmaceutics of spironolactone in man.","volume":"5","author":"Overdiek","year":"1987","journal-title":"Rev Drug Metab Drug Interact"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/94\/4\/1347\/10807172\/jcem1347.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/94\/4\/1347\/10807172\/jcem1347.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T00:55:34Z","timestamp":1594947334000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/94\/4\/1347\/2596590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,1]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2008-2054","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,1]]}}}